CA3121300A1 - Dpep-1 binding agents and methods of use - Google Patents

Dpep-1 binding agents and methods of use Download PDF

Info

Publication number
CA3121300A1
CA3121300A1 CA3121300A CA3121300A CA3121300A1 CA 3121300 A1 CA3121300 A1 CA 3121300A1 CA 3121300 A CA3121300 A CA 3121300A CA 3121300 A CA3121300 A CA 3121300A CA 3121300 A1 CA3121300 A1 CA 3121300A1
Authority
CA
Canada
Prior art keywords
peptide
dpep
binding
cells
lsalt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3121300A
Other languages
English (en)
French (fr)
Inventor
Stephen Mark Robbins
Donna Lorraine Senger
Daniel Abraham Muruve
Saurav Roy Choudhury
Jennifer Joy Rahn
Arthur Wing Sze LAU
Justin MACDONALD
Liane Babes
Paul Kubes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arch Biopartners Inc
Original Assignee
Arch Biopartners Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arch Biopartners Inc filed Critical Arch Biopartners Inc
Publication of CA3121300A1 publication Critical patent/CA3121300A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA3121300A 2018-11-30 2019-12-02 Dpep-1 binding agents and methods of use Pending CA3121300A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862773733P 2018-11-30 2018-11-30
US62/773,733 2018-11-30
PCT/IB2019/001289 WO2020109864A1 (en) 2018-11-30 2019-12-02 Dpep-1 binding agents and methods of use

Publications (1)

Publication Number Publication Date
CA3121300A1 true CA3121300A1 (en) 2020-06-04

Family

ID=70853301

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3121300A Pending CA3121300A1 (en) 2018-11-30 2019-12-02 Dpep-1 binding agents and methods of use

Country Status (7)

Country Link
US (3) US11286278B2 (https=)
EP (1) EP3887390A4 (https=)
JP (2) JP7535514B2 (https=)
AU (1) AU2019386379B2 (https=)
CA (1) CA3121300A1 (https=)
IL (1) IL283231B1 (https=)
WO (1) WO2020109864A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7535514B2 (ja) * 2018-11-30 2024-08-16 アーチ バイオパートナーズ， インコーポレイテッド Ｄｐｅｐ－１結合剤および使用の方法
EP4320167A4 (en) * 2021-04-08 2025-08-06 Nat Res Council Canada DPEP-1 BINDING AGENTS AND METHODS OF USE THEREOF
EP4574146A1 (en) 2023-12-18 2025-06-25 Telara Pharma S.L. Dhp-i inhibitors for use as neuroprotectants and in the treatment of neuroinflammatory diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223558B2 (en) * 2001-07-11 2007-05-29 Bristol-Myers Squibb Company Polynucleotides encoding three novel human cell surface proteins with leucine rich repeats and immunologobulin folds, BGS2, 3, and 4 and variants thereof
WO2007081751A2 (en) * 2006-01-05 2007-07-19 The Johns Hopkins University Compositions and methods for the treatment of cancer
EP2561359A1 (en) * 2010-04-20 2013-02-27 Addex Pharma SA Chimeric polypeptides useful in proximal and dynamic high-throughput screening methods
WO2012112420A1 (en) * 2011-02-14 2012-08-23 Allergan, Inc. Treatments using psma ligand endopeptidases
WO2015120536A1 (en) * 2014-02-13 2015-08-20 Arch Cancer Therapeutics, Inc. Peptides that block leukocyte recruitment and methods of use
ES3057215T3 (en) * 2015-08-11 2026-02-26 Arch Biopartners Inc Antagonist binding to dpep-1 for use in treating or preventing acute kidney injury or ischemia-reperfusion injury
EP3519443A4 (en) * 2016-09-30 2020-06-10 Baylor College of Medicine CHIMERIC ANTIGEN RECEPTOR THERAPY WITH REDUCED CYTOTOXICITY FOR VIRAL DISEASE
JP2019529499A (ja) * 2016-09-30 2019-10-17 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 組織指向性発現を用いた抗体ベースの遺伝子治療
JP7535514B2 (ja) * 2018-11-30 2024-08-16 アーチ バイオパートナーズ， インコーポレイテッド Ｄｐｅｐ－１結合剤および使用の方法

Also Published As

Publication number Publication date
EP3887390A4 (en) 2022-11-23
JP2024028553A (ja) 2024-03-04
AU2019386379B2 (en) 2025-05-22
US20220251140A1 (en) 2022-08-11
IL283231B1 (en) 2026-03-01
AU2019386379A1 (en) 2021-07-15
JP2022509258A (ja) 2022-01-20
JP7535514B2 (ja) 2024-08-16
US20200223888A1 (en) 2020-07-16
IL283231A (en) 2021-07-29
US11286278B2 (en) 2022-03-29
EP3887390A1 (en) 2021-10-06
US20250333443A1 (en) 2025-10-30
WO2020109864A1 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
US20250333443A1 (en) Dpep-1 binding agents and methods of use
US12569538B2 (en) DPEP-1 binding compositions and methods of use
AU2018216033B2 (en) Peptide modulators of the interaction between human C-peptide and human elastin receptor for therapeutic use
JP2010506860A (ja) Ｐ−糖タンパク質機能を刺激するための化合物およびその使用
US7374898B2 (en) Peptide inhibitors against seprase
DK1781315T3 (en) PEPTIDE INHIBITORS FOR MEDIATION OF stress responses
US9815867B2 (en) Peptide for inhibiting vascular endothelial growth factor receptor
JP2008505846A (ja) 悪性哺乳動物細胞および形質転換哺乳動物細胞に対して選択的に致死性を有するペプチド

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231128

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241114

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241114

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250618

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250925

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251121

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251121

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251121

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251125

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251125